Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 2016. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs). Specifically, it details the vesting and lapsing of conditional share awards under the 2009 Performance Share Plan and the 2009 Deferred Annual Bonus Plan for awards granted in 2013, measured over the performance period from January 1, 2013, to December 31, 2015.
Key Financial Metrics and Performance Outcomes
The filing does not report consolidated revenue, profit, cash flow, or debt metrics for the company. Instead, it focuses on executive compensation performance metrics tied to the 2013-2015 period:
- Adjusted Free Cash Flow: The company did not meet the threshold level of performance; this 25% component lapsed in full (0% vesting).
- Total Shareholder Return (TSR): GSK ranked 10th (below median) against a comparator group of 10 global pharmaceutical companies; this 25% component lapsed in full (0% vesting).
- R&D New Products Sales: Achieved sales of £6.192 billion, falling between the 75% vesting level (£6.013 billion) and the maximum level (£6.614 billion). This resulted in 82% vesting for this 25% component (20.5% total).
- Business Diversification: Due to the transformational three-part transaction with Novartis, the Remuneration Committee adjusted the target. Performance was deemed between threshold and maximum, resulting in 69% vesting for this 25% component (17.25% total).
- Total Vesting Outcome: The aggregate vesting for the 2013 Performance Share Plan awards was 37.75%.
Share Prices at Vesting (February 12, 2016):
- Ordinary Share: £13.635
- American Depositary Share (ADS): US$39.76
Material Changes and Executive Transactions
The primary material event is the partial vesting of executive equity awards based on the mixed performance results described above. Significant portions of the awards lapsed due to missed targets on free cash flow and TSR. Notable transactions include:
- Sir Andrew Witty (CEO): Vested 193,354 Ordinary Shares and 318,839 ADSs under the Performance Share Plan. Additionally, 36,441 Deferred Shares and 13,757 Matching Shares vested. A holding tranche of 48,339 ordinary shares (25% of vested shares) will be held back for two years.
- Other Executives: Various vested and lapsed amounts were recorded for other executive directors and PDMRs, including Mr. S. Dingemans, Dr. M. Slaoui, and Mr. P. Vallance.
- Deferred Bonus Plan: Matching shares for the Deferred Annual Bonus Plan also vested at the 37.75% rate consistent with the Performance Share Plan.
Guidance, Risks, and Unusual Items
Management Commentary and Adjustments: The Remuneration Committee explicitly noted that the original target for the Business Diversification measure was not sustainable due to the "transformational three-part transaction with Novartis." The committee reviewed performance in light of additional sales from the acquired Vaccines business and the Consumer Healthcare joint venture, leading to a discretionary vesting determination between the threshold and maximum levels.
Unusual Items: The filing highlights the significant impact of the Novartis transaction on performance metrics and the resulting adjustment to vesting calculations for the Business Diversification measure.
Risks and Contingencies: The filing does not disclose new operational risks or contingencies beyond the standard performance risks inherent in the equity plans, which resulted in significant lapses for cash flow and TSR metrics.
Key Facts for Investor Verification
- Verify the specific financial impact of the Novartis transaction on the "Business Diversification" metric and the rationale for the 69% vesting adjustment.
- Confirm the total dilution impact of the vested shares (Ordinary Shares and ADSs) on the company's share capital.
- Review the "holding tranche" agreement for Sir Andrew Witty to understand the timing of the release of the 48,339 held-back shares.
- Assess the correlation between the missed Adjusted Free Cash Flow and TSR targets and the company's broader strategic performance during the 2013-2015 period.